NAVICAN PRECISION CANCER CARE - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Serial Number
87468478
Word Mark
NAVICAN PRECISION CANCER CARE
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2019-02-04
Filing Date
2017-05-30
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2017-11-07
Attorney Name
Law Office Assigned Location Code
M80
Employee Name
LEASER, ANDREW C
Statements
Disclaimer with Predetermined Text
"PRECISION CANCER CARE"
Goods and Services
Assays and reagents for use in genetic research
Goods and Services
Medical diagnostic reagents and assays for testing of tumor tissue or body fluids
Goods and Services
Pharmaceutical benefit management services; insurance claims processing in the field of diagnostics and pharmaceutical claims; providing a database featuring information and statistics about patient reimbursement and insurance coverage for diagnostics and pharmaceuticals; reimbursement payment processing in the field of diagnostics and pharmaceutical claims; providing information in the field of financial support options and resources for prescribers, patients and the pharmaceutical industry; providing patient reimbursement and insurance coverage information in the field of drug reimbursement for prescribers, patients and the pharmaceutical industry; providing patient reimbursement and insurance coverage information in the field of diagnostics reimbursement for providers and patients; and financial administration of diagnostics and pharmacy reimbursement programs and services
Goods and Services
Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagants and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products
Classification Information
International Class
001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes
001, 005, 006, 010, 026, 046
Class Status Code
6 - Active
Class Status Date
2017-06-06
Primary Code
001
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2017-06-06
Primary Code
005
Correspondences
Name
JOSHUA G. GIGGER
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship Type | Reel Number |
Continuity Child | 87978077 |
Madrid International Filings
Entry Number
1
Reference Number
A0071255
Original Filing Date USPTO
2017-11-07
International Registration Number
1389030
International Registration Date
2017-11-07
International Status Code
480
International Renewal Date
2027-11-07
Madrid History Events | ||
Date | Code | Description |
2019-08-05 | CBPCP | PARTIAL CEASING OF EFFECT TO BE PROCESSED |
2018-04-23 | CBPCP | PARTIAL CEASING OF EFFECT TO BE PROCESSED |
2018-07-14 | DBCRP | DIVISIONAL OF BASE APP NOTICE CREATED, TO BE SENT TO IB |
2017-11-07 | NEWAP | NEW APPLICATION FOR IR RECEIVED |
2019-08-07 | CBMPP | CEASING OF EFFECT PROCESSED |
2019-08-07 | CBPSP | PARTIAL CEASING OF EFFECT NOTICE SENT TO IB |
2017-11-08 | MCERT | MANUALLY CERTIFIED |
2017-11-08 | APPST | IR CERTIFIED AND SENT TO IB |
2019-09-04 | CBPCP | PARTIAL CEASING OF EFFECT TO BE PROCESSED |
2019-10-04 | PCBNP | PARTIAL CEASING OF EFFECT PROCESSED BY IB |
2018-01-12 | IRRAC | RESPONSE TO IRREGULARITY REVIEWED AND ACCEPTED |
2018-01-12 | IRSNT | IRREGULARITY RESPONSE SENT TO IB |
2018-01-02 | IRRCV | IRREGULARITY RESPONSE RECEIVED FROM APPLICANT |
2017-12-05 | IRREG | IRREGULARITY NOTICE RECEIVED FROM IB |
2018-02-15 | CREAT | APPLICATION FOR IR REGISTERED BY IB |
2019-09-18 | CBNAR | CEASING OF EFFECT REVIEWED - NO ACTION REQUIRED BY OFFICE |
2018-07-16 | DBCSP | DIVISIONAL OF BASE APP NOTICE SENT TO IB |
2019-10-17 | CHGOW | CHANGE OF OWNER RECEIVED FROM IB |
2019-10-17 | CHGOW | CHANGE OF OWNER RECEIVED FROM IB |
2018-04-26 | CBNAR | CEASING OF EFFECT REVIEWED - NO ACTION REQUIRED BY OFFICE |
2018-08-24 | PDBNX | DIVISION OF BASE APPLICATION PROCESSED BY IB |
Trademark Events
Event Date | Event Description |
2017-06-02 | NEW APPLICATION ENTERED IN TRAM |
2017-06-06 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2017-08-17 | ASSIGNED TO EXAMINER |
2017-08-24 | EXAMINERS AMENDMENT -WRITTEN |
2017-08-24 | EXAMINERS AMENDMENT E-MAILED |
2017-08-24 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2017-08-24 | EXAMINER'S AMENDMENT ENTERED |
2017-08-26 | EXAMINERS AMENDMENT -WRITTEN |
2017-08-26 | EXAMINERS AMENDMENT E-MAILED |
2017-08-26 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2017-08-26 | EXAMINER'S AMENDMENT ENTERED |
2017-09-16 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2017-10-01 | ASSIGNED TO LIE |
2017-10-18 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2017-11-07 | PUBLISHED FOR OPPOSITION |
2017-11-07 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2018-01-02 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2018-06-29 | TEAS EXTENSION RECEIVED |
2018-06-29 | TEAS REQUEST TO DIVIDE RECEIVED |
2018-07-13 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2018-06-29 | DIVISIONAL REQUEST RECEIVED |
2018-07-13 | DIVISIONAL PROCESSING COMPLETE |
2018-06-29 | EXTENSION 1 FILED |
2018-07-13 | EXTENSION 1 GRANTED |
2018-07-14 | CORRECTED NOA E-MAILED |
2018-07-14 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2019-02-04 | ABANDONMENT - NO USE STATEMENT FILED |
2019-02-04 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |